The systemic virotherapy strategy involves not only the direct delivery of therapeutic payloads encoded by viruses to tumors, but also the modification of the tumor microenvironment, aiming to target both primary and metastatic lesions. At the ongoing American Society of Clinical Oncology (ASCO) meeting, researchers from Calidi Biotherapeutics Inc. reported the development of a novel approach using a selected and engineered tumor-selective strain of vaccinia virus.
An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22 cancer types, which has identified more than 9,000 proteins from 1,000 tumors. The results reveal which proteins allow for the classification of different cancer types, biomarkers and potential therapeutic targets, which are now available to the entire scientific community.
Despite the advancement of AI and machine learning technologies and their incorporation into cancer treatment and drug development, a lack of trust and understanding of these new approaches is impeding care and treatment.
Mabwell (Shanghai) Bioscience Co. Ltd. on May 30 gained Chinese approval of Mailisheng (albipagrastim alfa; 8MW-0511) as a subcutaneous injection to treat febrile neutropenia induced by myelosuppressive anticancer treatment, such as radiotherapy and chemotherapy.
Samsung Medical Center spinoff Aimedbio Inc. announced raising ₩51.1 billion (US$37.15 million) in pre-IPO funding to advance its portfolio of clinical and preclinical antibody-drug conjugate (ADC) candidates.
New and positive phase III cancer data for two monoclonal antibodies from two pharma giants opened the second day of the American Society of Clinical Oncology (ASCO) conference this past weekend.
More phase III data coursed through the annual American Society of Clinical Oncology (ASCO) conference on Sunday, as Protagonist Therapeutics Inc. and Takeda Pharmaceutical Co. Ltd. led the charge with positive results for its potential blockbuster rusfertide in treating a rare leukemia.
At the 61st American Society of Clinical Oncology (ASCO) Annual Meeting, multiple companies presented clinical trial data showing their drugs and devices helped patients with pancreatic cancer live longer or improve their ability to respond to treatment.
Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 billion. BNT-327 is in the hot new class of bispecific antibodies targeting programmed death-1 (PD-1) or its ligand (PD-L1) and vascular endothelial growth factor (VEGF). The bispecifics take advantage of two well established mechanisms of action that help tumors grow; PD-1/PD-L1, which tells immunogenic T cells not to attack the tumor, and VEGF, which tumors excrete to produce new blood vessels to supply oxygen and other nutrients to the tumor.
Gan & Lee Pharmaceuticals Co. Ltd. has described protein cereblon (CRBN) inhibitors and proteolysis targeting chimera (PROTAC) compounds reported to be useful for the treatment of cancer.